TScan Therapeutics' (TCRX) "Buy" Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX - Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $11.00 price objective on the stock.

TCRX has been the topic of several other research reports. HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of TScan Therapeutics in a report on Tuesday, August 13th. Wedbush reiterated an "outperform" rating and issued a $10.00 price target on shares of TScan Therapeutics in a report on Tuesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $12.00.

TScan Therapeutics Stock Performance

NASDAQ:TCRX traded up $0.40 during midday trading on Wednesday, reaching $5.69. The stock had a trading volume of 1,135,977 shares, compared to its average volume of 246,558. The stock has a market cap of $301.40 million, a P/E ratio of -4.90 and a beta of 0.79. The company has a quick ratio of 7.77, a current ratio of 7.77 and a debt-to-equity ratio of 0.08. TScan Therapeutics has a 12-month low of $3.73 and a 12-month high of $9.69. The firm has a fifty day simple moving average of $5.34 and a two-hundred day simple moving average of $6.58.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.02. The business had revenue of $0.54 million for the quarter, compared to analysts' expectations of $1.55 million. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. On average, equities analysts expect that TScan Therapeutics will post -1.17 EPS for the current year.

Insider Activity

In related news, Director Barbara Klencke purchased 5,000 shares of the company's stock in a transaction that occurred on Monday, August 26th. The shares were purchased at an average price of $5.53 per share, with a total value of $27,650.00. Following the purchase, the director now owns 40,000 shares of the company's stock, valued at $221,200. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Barbara Klencke bought 5,000 shares of the firm's stock in a transaction on Monday, August 26th. The stock was bought at an average price of $5.53 per share, with a total value of $27,650.00. Following the purchase, the director now directly owns 40,000 shares of the company's stock, valued at approximately $221,200. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $5.78, for a total value of $951,885.08. Following the sale, the insider now owns 4,716 shares of the company's stock, valued at approximately $27,258.48. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders purchased 15,000 shares of company stock worth $82,550. Insiders own 2.76% of the company's stock.

Hedge Funds Weigh In On TScan Therapeutics

Several hedge funds have recently bought and sold shares of TCRX. Dimensional Fund Advisors LP acquired a new position in shares of TScan Therapeutics during the 2nd quarter worth about $70,000. SG Americas Securities LLC acquired a new position in shares of TScan Therapeutics during the third quarter worth approximately $78,000. The Manufacturers Life Insurance Company bought a new stake in shares of TScan Therapeutics in the second quarter valued at approximately $90,000. Cornercap Investment Counsel Inc. acquired a new stake in shares of TScan Therapeutics in the second quarter worth $134,000. Finally, Rhumbline Advisers acquired a new stake in shares of TScan Therapeutics in the second quarter worth $274,000. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.